Pramipexole, a dopamine D3/D2 receptor-preferring agonist, attenuates reserpine-induced fibromyalgia-like model in mice

Martins, Carlos Pereira; Paes, Rodrigo Sebben; Baldasso, Gabriela Mantovani; Ferrarini, Eduarda Gomes; Scussel, Rahisa; Zaccaron, Rubya Pereira; Machado-de-Ávila, Ricardo Andrez; Dutra, Rafael Cypriano

doi:10.4103/1673-5374.317984

Cited by 17 publications

(8 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, acute and subacute (10 days) systemic posttreatment with PPX reverted thermal and mechanical allodynia (Cao et al, 2016; Romero‐Sánchez et al, 2020) and hyperalgesia in rats with Parkinson's disease (Romero‐Sánchez et al, 2020). Intraperitoneal posttreatment administration with PPX (4 days) blocked the mechanical and thermal allodynia during the fibromyalgia‐like model in mice (Martins et al, 2022). Finally, a clinical study showed that oral treatment with PPX (14 weeks) significantly decreased pain in patients with fibromyalgia (Holman & Myers, 2005).…”

Section: Discussionmentioning

confidence: 99%

“…Dopamine plays a potential role in antinociception and analgesia (Wood, 2008), principally through activating D2 (and likely D3) receptors (Mansikka et al, 2005; Wood, 2008). Low dopamine levels contribute to the painful symptoms presented by patients with Parkinson's disease (Peng et al, 2006), fibromyalgia, and diabetic neuropathy (Martins et al, 2022). However, the mechanisms by which dopamine or D2/D3 receptor agonists exert an antinociceptive effect are not entirely understood.…”

Section: Introductionmentioning

confidence: 99%

“…PPX prevents the development of inflammation induced by carrageenan, formalin, and tissue plasminogen activator (TPA) (Sadeghi et al, 2017). In addition, studies have demonstrated that PPX inhibits thermal (Cao et al, 2016; Martins et al, 2022) and mechanical (Edwards et al, 2022; Romero‐Sánchez et al, 2020) nociception hypersensitivity in animals with Parkinson's disease, fibromyalgia, and inflammatory pain. This evidence suggests the potential usefulness of PPX as an antinociceptive agent.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pramipexole inhibits formalin‐induce acute and long‐lasting mechanical hypersensitivity via NF‐kB pathway in rats

Santamaria‐Anzures

Pérez‐Ramos

Mendoza‐Pérez

et al. 2023

Drug Development Research

View full text Add to dashboard Cite

Pain is one of the most frequent causes for patients to seek medical care. It interferes with daily functioning and affects the quality of life of the patient. There is a clear need to investigate nonopioid or non-nonsteroidal anti-inflammatory drug alternatives for the treatment of pain. In this study, we determined the effect of acute pre-and posttreatment with pramipexole (PPX), a dopamine D2/D3 selective agonist, on formalin 1%-induced acute and long-lasting nociceptive behavior sensitivity in rats.Moreover, we sought to investigate whether the antiallodynic and antihyperalgesic effect induced by PPX was mediated through the nuclear factor-κB (NF-kB) signaling pathway. Moreover, acute systemic pretreatment with PPX (1 and 3 mg/kg, ip) suppressed the formalin-induced nociceptive behavior during both phases of the formalin test and the development of formalin-induced secondary mechanical allodynia and hyperalgesia in both paws. Acute systemic posttreatment with PPX (3 mg/kg, ip) reverted the formalin-induced long-lasting secondary mechanical allodynia and hyperalgesia. Furthermore, PPX inhibits the protein expression of NF-κB-p65 and the levels of tumor necrosis factor-α and interleukin-1β in the spinal cord of animals with secondary mechanical allodynia and hyperalgesia induced by formalin. These data suggest that PPX has a potential role in producing anti-inflammatory activity.Moreover, the antiallodynic and antihyperalgesic effects induced by PPX can be mediated through the NF-kB signaling pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pramipexole inhibits formalin‐induce acute and long‐lasting mechanical hypersensitivity via NF‐kB pathway in rats

Santamaria‐Anzures

Pérez‐Ramos

Mendoza‐Pérez

et al. 2023

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…Given the demonstrated analgesic effects of tianeptine in animal models, future research could investigate the potential of tianeptine as a treatment option for fibromyalgia patients [ 86 ]. Pramipexole, a dopamine agonist previously studied for fibromyalgia, could be further investigated in clinical trials as a potential treatment option for fibromyalgia patients, particularly in terms of its effects on pain, fatigue, and sleep [ 87 ].…”

Section: Reviewmentioning

confidence: 99%

Beyond the Pain: A Systematic Narrative Review of the Latest Advancements in Fibromyalgia Treatment

Ram,

Jeyaraman,

Jeyaraman

et al. 2023

Cureus

View full text Add to dashboard Cite

Fibromyalgia is a complex chronic pain disorder that significantly impacts the quality of life of affected individuals. The etiology of fibromyalgia remains elusive, necessitating effective treatment options. This review aims to provide an overview of current treatment options for fibromyalgia and highlight recent updates in managing the condition. The methodology employed in this systematic review comprised the following key steps. We conducted a comprehensive search across various databases to identify pertinent studies published between 2000 and 2023. Inclusion criteria were defined to specifically target studies involving adult individuals diagnosed with fibromyalgia, with a focus on both pharmacological and non-pharmacological interventions for managing the condition. The review encompassed a range of study types, including randomized controlled trials, observational studies, and systematic reviews. To ensure the quality of the selected studies, we employed appropriate assessment tools, and data extraction and synthesis adhered to established guidelines. This rigorous approach allowed for a robust analysis of the literature on fibromyalgia management. In the course of our review, it became evident that a spectrum of treatment approaches holds significant promise in the management of fibromyalgia. Specifically, pharmacological interventions, including selective serotonin-norepinephrine reuptake inhibitors, anticonvulsants, cannabinoids, tropisetron, and sodium oxybate, have exhibited substantial potential in alleviating fibromyalgia symptoms. Concurrently, non-pharmacological strategies, such as cognitive-behavioral therapy, exercise regimens, and complementary and alternative therapies, have yielded positive outcomes in improving the condition's management. Recent developments in the field have introduced innovative pharmacological agents like milnacipran and pregabalin, in addition to non-pharmacological interventions like mindfulness-based stress reduction and aquatic exercise, expanding the array of options available to enhance fibromyalgia care and alleviating patient symptoms. Fibromyalgia necessitates a multidisciplinary approach to treatment, encompassing both pharmacological and non-pharmacological interventions. Recent updates in fibromyalgia management offer additional options to alleviate symptoms and improve the quality of life for individuals with fibromyalgia. Healthcare professionals should remain informed about these advancements to provide evidence-based care, addressing the complex symptoms associated with fibromyalgia and enhancing patient outcomes.

show abstract

“…It is commonly supposed that high level of dopamine can potentially affect heart health, leading to increased heart rate, high blood pressure, heart failure, and other diseases [2]. Low level of dopamine in the central nervous system is responsible for many neurological disorder, including Parkinson's disease, schizophrenia, Alzheimer's disease, depression, etc [3][4][5][6]. Uric acid (UA) is the major end product of purine metabolism.…”

Section: Introductionmentioning

confidence: 99%

Porous carbon nanosheets derived from two-dimensional Fe-MOF for simultaneous voltammetric sensing of dopamine and uric acid

Chen,

Zhou,

et al. 2023

Nanotechnology

View full text Add to dashboard Cite

It is of great significance for electrochemical sensors to simultaneously detect dopamine (DA) and uric acid (UA) related to biological metabolism. In this work, two-dimensional (2D) porous carbon nanosheets (CNS) was prepared as electrocatalysts to improve the sensitivity, the selectivity, and the detection limit of the simultaneous detection. First, 2D amorphous iron-metal organic frameworks (Fe-MOF) was synthesized with Fe3+ and terephthalic acid via a facile wet chemistry method at room temperature. And then, CNS was prepared by pyrolysis and pickling of Fe-MOF. CNS had large specific surface area, good electrical conductivity and lots of carbon defects. The response currents of the CNS modified electrode was larger than those of the control electrodes in the simultaneous determination. The simultaneous determination were measured via difference pulse voltammetry to reduce the effect of capacitive currents on quantitative analysis. The CNS modified electrodes showed high sensitivity and low detection limit for the simultaneous detection of DA and UA. The modified electrodes have been successfully used to detect DA and UA in normal human serum.

show abstract

Pramipexole, a dopamine D3/D2 receptor-preferring agonist, attenuates reserpine-induced fibromyalgia-like model in mice

Cited by 17 publications

References 69 publications

Pramipexole inhibits formalin‐induce acute and long‐lasting mechanical hypersensitivity via NF‐kB pathway in rats

Pramipexole inhibits formalin‐induce acute and long‐lasting mechanical hypersensitivity via NF‐kB pathway in rats

Beyond the Pain: A Systematic Narrative Review of the Latest Advancements in Fibromyalgia Treatment

Porous carbon nanosheets derived from two-dimensional Fe-MOF for simultaneous voltammetric sensing of dopamine and uric acid

Contact Info

Product

Resources

About